IBI188 Combination Therapy in Solid Tumors

  • End date
    Oct 31, 2022
  • participants needed
  • sponsor
    Innovent Biologics (Suzhou) Co. Ltd.
Updated on 28 July 2021
measurable disease
colony stimulating factor


A Phase Ib study aim to explore the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies

Condition Osteosarcoma, Sarcoma, Solid Tumors, Solid Neoplasm, Lung Adenocarcinoma, Solid Tumour, bone sarcoma
Treatment bevacizumab, Pemetrexed, GM-CSF, Cisplatin/Carboplatin, Sintilimab, IBI188
Clinical Study IdentifierNCT04861948
SponsorInnovent Biologics (Suzhou) Co. Ltd.
Last Modified on28 July 2021


Yes No Not Sure

Inclusion Criteria

Patients with locally advanced or metastatic solid tumors cannot be cured by surgery or other local treatments
Aged 18 years ( 12 years is acceptable in Cohort C)
Able to provide archived or fresh tumor tissue samples for biomarker assessment
Have at least one measurable lesion according to RECIST version 1.1
ECCG PS score of 0-2
Adequate organ and bone marrow functions
Life expectancy 12 weeks
Female subjects of childbearing potential or male subjects with partners of childbearing potential should take effective contraceptive measures throughout the whole treatment period and until 6 months after treatment
Must voluntarily sign the Informed Consent Form (ICF), and be able to follow all study requirements and procedures. For the subjects enrolled in Cohort C who are 12 and < 18 years old, in addition to obtaining the child's own consent, their guardians should provide informed consent and sign the ICF

Exclusion Criteria

Previous exposure to any CD47 antibody, SIRP antibody, CD47/SIRP recombinant protein or other inhibitors that act in the same pathway
Previous exposure to any anti-programmed death receptor 1 (PD-1) or anti-programmed death-ligand (PD-L1) antibody (except Cohort C)
Concurrent participation in another clinical study
The last dose of anti-tumor therapy is within 4 weeks before the first dose of study treatment
Have undergone major surgical procedures within 4 weeks prior to the first dose of study treatment or planned to receive major surgery during the study treatment
Presence of toxicities (excluding alopecia and fatigue) induced by previous anti-tumor therapy that has not recovered to Grade 0 or 1 as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 prior to the first dose of study treatment
Known hypersensitivity to IBI188 or any ingredient in the study drug product
History of other primary malignancies
Female subjects who are pregnant or lactating
Other ineligible conditions considered by the investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note